The human nervous system is well protected by the Blood Brain Barrier (BBB), which renders selectivity as well as protection to the human nervous tissue. The BBB not only promotes biochemical responses in the brain, but also acts as a defending barrier against many harmful pathogens and certain chemical entities as well as drug molecules. This inbuilt security acts as a checkpoint to facilitate the flow of particularly those drug molecules administered for the treatment of various diseases or disorders. Cerebrovascular disorders like ischemia and acute arterial thrombosis accounts to the major causes of mortality and morbidity worldwide. Treatment of cerebral ischemia needs the instantaneous administration of those thrombolytic agents that can easily cross the protective barrier and enter into the systemic circulation. However, thrombolytics possess certain limitations when used for cerebral disorders because of its low penetrability in the BBB. This results in development of drug dependent toxicity and tissue-level neuronal damage. To combat this scenario various nanoparticle targeting approaches have been built to fight against the cerebrovascular disorders. These nanoparticle approaches add to the advantage over other drug delivery carriers in terms of high permeability, least toxicity and more bioavailability.Up to 350 words. No references allowed. Abstracts may be submitted at a later date.